FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2383350224> ?p ?o ?g. }

• W2383350224 endingPage "S305" @default.
• W2383350224 startingPage "S305.3" @default.
• W2383350224 abstract "<h3>Introduction</h3> Inducible 6-phosphofructo-2-kinase (iPFK-2; PFKFB3) has been found to be overexpressed by the neoplastic cells of human solid tumors, required for human leukemia growth in athymic mice and to be a transcriptional target of hypoxia inducible factor 1, a protein required for the survival and growth of tumors. Based on these observations, the substrate (fructose-6-phosphate) binding site of iPFK-2 is an attractive target for the identification of pharmacophore-based compounds as antineoplastic agents. <h3>Methods/Results</h3> The x-ray structures of human liver and rat testes PFKFB isozymes served as input homologue sequences and structural templates for the determination of structurally conserved regions and the fructose-6-phosphate (F6P) binding site of iPFK-2. The Advanced Chemical Directory (v.2002-2) then was computationally screened for high fit molecules of the F6P binding site of iPFK-2 and 45 compounds were identified. We exposed Jurkat human T cell leukemia cells to 6 of the compounds (termed MT1-6) at concentrations of 100 nM-1 mM, and then enumerated live and dead cells by propidium iodide exclusion staining after 48-72 hours of exposure. Whereas 5 compounds exhibited cytotoxic effects at a concentration of 1 mM, compound MT3 was cytotoxic at a concentration of 10 μM and cytostatic at a concentration of 1 μM in vitro. Growth inhibitory properties of MT3 were also observed against A459 human lung adenocarcinoma cells, mouse Lewis lung carcinoma cells, and mouse B16 melanoma cells. Exposure of MT3 to Jurkat cells suppressed (i) the product of iPFK-2, F2,6BP; (ii) lactate secretion; and (iii) incorporation of glucose-derived carbons into pyrimidine but not purine riboses via the pentose shunt. Toxicity studies in C57BL/6 mice indicated that daily intraperitoneal administration of 0.5 mg of compound MT3 was well tolerated. We subcutaneously injected 8 × 105 Lewis lung carcinoma cells (in 100 μL PBS) into C57Bl/6 mice and, after tumors were established, administered 0.5 mg MT3 or vehicle i.p. every 24 hours. After 14 days we observed a reduction in tumor growth in mice that were administered daily MT3 (1042.8 ± 192.5 mm3) compared to vehicle alone (2034.78 ± 395.18 mm3; p value < .0001). <h3>Conclusions</h3> We conclude that pharmacophore targeting of the substrate binding site of iPFK-2 may prove to be a useful strategy in the development of novel antineoplastic agents. The selective reduction of 13C-glucose incorporation into pyrimidine riboses suggests that MT3 may decrease the availability of aspartate, a product of the citric acid cycle (via oxaloacetate) and a precursor of the pyrimidine ring." @default.
• W2383350224 created "2016-06-24" @default.
• W2383350224 creator A5025226546 @default.
• W2383350224 creator A5029157205 @default.
• W2383350224 creator A5041765132 @default.
• W2383350224 creator A5054078915 @default.
• W2383350224 creator A5054533184 @default.
• W2383350224 creator A5062703812 @default.
• W2383350224 creator A5071197441 @default.
• W2383350224 creator A5086165685 @default.
• W2383350224 creator A5089071397 @default.
• W2383350224 date "2005-01-01" @default.
• W2383350224 modified "2023-09-26" @default.
• W2383350224 title "294 PHARMACOPHORE TARGETING OF THE FRUCTOSE-6-PHOSPHATE BINDING SITE OF IPFK-2 SUPPRESSES TUMOR GROWTH" @default.
• W2383350224 doi "https://doi.org/10.2310/6650.2005.00006.293" @default.
• W2383350224 hasPublicationYear "2005" @default.
• W2383350224 type Work @default.
• W2383350224 sameAs 2383350224 @default.
• W2383350224 citedByCount "0" @default.
• W2383350224 crossrefType "journal-article" @default.
• W2383350224 hasAuthorship W2383350224A5025226546 @default.
• W2383350224 hasAuthorship W2383350224A5029157205 @default.
• W2383350224 hasAuthorship W2383350224A5041765132 @default.
• W2383350224 hasAuthorship W2383350224A5054078915 @default.
• W2383350224 hasAuthorship W2383350224A5054533184 @default.
• W2383350224 hasAuthorship W2383350224A5062703812 @default.
• W2383350224 hasAuthorship W2383350224A5071197441 @default.
• W2383350224 hasAuthorship W2383350224A5086165685 @default.
• W2383350224 hasAuthorship W2383350224A5089071397 @default.
• W2383350224 hasConcept C109316439 @default.
• W2383350224 hasConcept C121608353 @default.
• W2383350224 hasConcept C153911025 @default.
• W2383350224 hasConcept C154317977 @default.
• W2383350224 hasConcept C179464577 @default.
• W2383350224 hasConcept C185592680 @default.
• W2383350224 hasConcept C190283241 @default.
• W2383350224 hasConcept C202751555 @default.
• W2383350224 hasConcept C203014093 @default.
• W2383350224 hasConcept C2775934118 @default.
• W2383350224 hasConcept C2776090121 @default.
• W2383350224 hasConcept C2777847059 @default.
• W2383350224 hasConcept C2779013556 @default.
• W2383350224 hasConcept C2779707156 @default.
• W2383350224 hasConcept C31573885 @default.
• W2383350224 hasConcept C502942594 @default.
• W2383350224 hasConcept C54355233 @default.
• W2383350224 hasConcept C55493867 @default.
• W2383350224 hasConcept C56173144 @default.
• W2383350224 hasConcept C86803240 @default.
• W2383350224 hasConcept C8891405 @default.
• W2383350224 hasConceptScore W2383350224C109316439 @default.
• W2383350224 hasConceptScore W2383350224C121608353 @default.
• W2383350224 hasConceptScore W2383350224C153911025 @default.
• W2383350224 hasConceptScore W2383350224C154317977 @default.
• W2383350224 hasConceptScore W2383350224C179464577 @default.
• W2383350224 hasConceptScore W2383350224C185592680 @default.
• W2383350224 hasConceptScore W2383350224C190283241 @default.
• W2383350224 hasConceptScore W2383350224C202751555 @default.
• W2383350224 hasConceptScore W2383350224C203014093 @default.
• W2383350224 hasConceptScore W2383350224C2775934118 @default.
• W2383350224 hasConceptScore W2383350224C2776090121 @default.
• W2383350224 hasConceptScore W2383350224C2777847059 @default.
• W2383350224 hasConceptScore W2383350224C2779013556 @default.
• W2383350224 hasConceptScore W2383350224C2779707156 @default.
• W2383350224 hasConceptScore W2383350224C31573885 @default.
• W2383350224 hasConceptScore W2383350224C502942594 @default.
• W2383350224 hasConceptScore W2383350224C54355233 @default.
• W2383350224 hasConceptScore W2383350224C55493867 @default.
• W2383350224 hasConceptScore W2383350224C56173144 @default.
• W2383350224 hasConceptScore W2383350224C86803240 @default.
• W2383350224 hasConceptScore W2383350224C8891405 @default.
• W2383350224 hasIssue "1" @default.
• W2383350224 hasLocation W23833502241 @default.
• W2383350224 hasOpenAccess W2383350224 @default.
• W2383350224 hasPrimaryLocation W23833502241 @default.
• W2383350224 hasRelatedWork W1500704576 @default.
• W2383350224 hasRelatedWork W1990434843 @default.
• W2383350224 hasRelatedWork W2036492511 @default.
• W2383350224 hasRelatedWork W2037693796 @default.
• W2383350224 hasRelatedWork W2070449743 @default.
• W2383350224 hasRelatedWork W2075644014 @default.
• W2383350224 hasRelatedWork W2119911486 @default.
• W2383350224 hasRelatedWork W2372802653 @default.
• W2383350224 hasRelatedWork W2383350224 @default.
• W2383350224 hasRelatedWork W4319867226 @default.
• W2383350224 hasVolume "53" @default.
• W2383350224 isParatext "false" @default.
• W2383350224 isRetracted "false" @default.
• W2383350224 magId "2383350224" @default.
• W2383350224 workType "article" @default.